imipramine has been researched along with Triple Negative Breast Neoplasms in 2 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
Excerpt | Relevance | Reference |
---|---|---|
" Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities." | 8.12 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ( Abdelfattah, N; Brenner, A; Chen, Y; Jatoi, I; Kaklamani, V; Nirzhor, S; Rajamanickam, S; Rao, A; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Viswanadhapalli, S, 2022) |
" Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities." | 4.12 | The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ( Abdelfattah, N; Brenner, A; Chen, Y; Jatoi, I; Kaklamani, V; Nirzhor, S; Rajamanickam, S; Rao, A; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Viswanadhapalli, S, 2022) |
"Imipramine is a tricyclic antidepressant that possesses anti-inflammatory activity and has been reported to inhibit the progression of highly metastatic non-small cell lung cancer." | 1.91 | Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells. ( Chen, SK; Chen, WT; Hsu, FT; Lee, W; Li, YC, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Timilsina, S | 1 |
Rajamanickam, S | 1 |
Rao, A | 1 |
Subbarayalu, P | 1 |
Nirzhor, S | 1 |
Abdelfattah, N | 1 |
Viswanadhapalli, S | 1 |
Chen, Y | 1 |
Jatoi, I | 1 |
Brenner, A | 1 |
Rao, MK | 1 |
Vadlamudi, R | 1 |
Kaklamani, V | 1 |
Chen, SK | 1 |
Lee, W | 1 |
Li, YC | 1 |
Hsu, FT | 1 |
Chen, WT | 1 |
2 other studies available for imipramine and Triple Negative Breast Neoplasms
Article | Year |
---|---|
The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
Topics: Animals; Antidepressive Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Repair; | 2022 |
Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Huma | 2023 |